HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IONS
Ionis Pharmaceuticals, Inc.
IONS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IONS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
IONS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IONS PE Valuation
IONS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IONS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
IONS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IONS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.32 | -$1.63 |
| Q2 2026 | -$3.46 | -$1.62 |
| Q1 2026 | -$2.07 | +$0.92 |
| Q4 2025 | -$2.44 | +$0.60 |
| Q3 2025 | -$1.69 | +$0.75 |
| Q2 2025 | -$1.84 | +$0.68 |
| Q1 2025 | -$2.99 | -$0.32 |
| Q4 2024 | -$3.04 | -$0.48 |
IONS is still losing money, but less than at its worst: $3.32 per share over the past year, against $4.23 at its worst in late 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IONS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IONS on profitability, with a higher operating margin.
IONS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $242.7M | +55% |
| Q2 2026 | $267.9M | -41% |
| Q1 2026 | $246.1M | +87% |
| Q4 2025 | $203.3M | -10% |
| Q3 2025 | $156.7M | +17% |
| Q2 2025 | $452M | +101% |
| Q1 2025 | $131.6M | +10% |
| Q4 2024 | $226.6M | -30% |
IONS's revenue is recovering but still below its 2019 peak: $243M last quarter, up 55% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -54% | +48 points |
| Q2 2026 | -38% | -69 points |
| Q1 2026 | -48% | +64 points |
| Q4 2025 | -105% | -57 points |
| Q3 2025 | -102% | +8.9 points |
| Q2 2025 | 31% | +60 points |
| Q1 2025 | -112% | +14 points |
| Q4 2024 | -49% | -47 points |
IONS's operating margin was −54% last quarter, up 48 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IONS on cash generation, producing positive trailing cash flow while its opponent burns cash.
IONS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$192.1M | -$55.4M |
| Q2 2026 | $549.5M | +295% |
| Q1 2026 | -$814.6M | -$651.2M |
| Q4 2025 | -$159M | -$17.4M |
| Q3 2025 | -$136.7M | -$12.7M |
| Q2 2025 | $139M | +$265.1M |
| Q1 2025 | -$163.4M | -$8.9M |
| Q4 2024 | -$141.6M | -520% |
IONS has burned cash in most quarters: −$616M over the past year, against −$303M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IONS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IONS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +786K shares |
| 1 year | +4% | +6.4M shares |
| 3 years | +16% | +22.9M shares |
| 5 years | +18% | +25.1M shares |
| Available history | +8.4% | +12.9M shares |
IONS has 166M diluted shares, up 4% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $52,000 |
| Q1 2020 | $90.6M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IONS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -8.8x | Net Cash |
| Q2 2022 | -56.9x | Net Cash |
| Q1 2022 | -24.7x | Net Cash |
| Q3 2020 | -5.0x | Net Cash |
| Q2 2020 | -3.2x | Net Cash |
| Q1 2020 | -2.5x | Net Cash |
| Q4 2019 | -1.8x | Net Cash |
IONS has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IONS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.4 | Oversold |
| Stochastic | 3.6 | Oversold |
IONS's weekly RSI is 21 (oversold) and its Stochastic is 4 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IONS PE vs Healthcare Sector
| Metric | IONS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
IONS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IONS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $41.2 | 34% below |
| 20 week MA | $51.2 | 47% below |
| 50 week MA | $66.9 | 59% below |
| 100 week MA | $55.6 | 51% below |
| 200 week MA | $49.0 | 44% below |
IONS is in a downtrend: it's below all five of its weekly moving averages, and 44% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over IONS on returns for 2026, with the stronger performance.
IONS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.8 | $59.7 | -1.8% |
| 2021 | $59.7 | $32.7 | -45% |
| 2022 | $32.7 | $38.2 | +17% |
| 2023 | $38.2 | $50.6 | +33% |
| 2024 | $50.6 | $35.9 | -29% |
| 2025 | $35.9 | $79.9 | +123% |
| 2026 YTD | $79.9 | $27.3 | -66% |
IONS's yearly returns have swung widely, from +123% in 2025 to −45% in 2021. It's down 66% so far in 2026.